Biogen INC Form 4 insider transactions

Biogen Inc. director William A. Hawkins was granted 1,505 restricted stock units as part of his director compensation.

Biogen Inc. director Stephen A. Sherwin was granted 1,505 restricted stock units as part of his compensation.

Biogen Inc. director Eric K. Rowinsky was granted 1,505 restricted stock units as part of his compensation package.

Biogen Inc. director Jesus B. Mantas acquired 1,505 restricted stock units as part of an equity compensation grant.

Biogen Inc. director Susan Langer was granted 1,505 restricted stock units as part of an equity compensation arrangement.

Biogen Inc. director Monish D. Patolawala was granted 1,505 restricted stock units as part of his director compensation.

Biogen Inc. Director Menelas N. Pangalos acquired 3,875 shares of common stock through the vesting of restricted stock units.

Biogen Inc. director Lloyd Minor was granted 1,505 restricted stock units as part of his compensation package.

Biogen Inc. director Maria C. Freire was granted 2,005 restricted stock units as part of standard equity compensation.

Biogen Inc. executive Adam Keeney reported transactions involving company stock, including the acquisition of restricted stock units and the disposition of common stock.

Biogen Inc. Chief Accounting Officer Sean Godbout reported transactions involving company stock and restricted stock units.

Biogen President and CEO Christopher Viehbacher exercised restricted stock units and subsequently sold shares to cover tax obligations.

Priya Singhal, Biogen's Head of Development, reported multiple transactions involving common stock, including RSU exercises, tax withholdings, and a sale, all executed under a Rule 10b5-1 plan.

Biogen's Head of Pharmaceutical Operations and Technology, Nicole Murphy, reported the exercise of restricted stock units and subsequent stock dispositions.

Biogen CFO Robin Kramer reported multiple transactions involving common stock and restricted stock units, primarily related to RSU vesting and tax withholdings.

Biogen's Head of Corporate Development, Adam Keeney, reported the acquisition of common stock through RSU vesting and subsequent sale of shares for tax obligations.

Biogen's Head of Global Product Strategy, Rachid Izzar, reported the vesting of restricted stock units and subsequent common stock transactions, including tax withholdings.

Biogen's Head of Research, Jane Grogan, reported the acquisition of restricted stock units and the disposition of common stock for tax withholding purposes.

Biogen's EVP of Human Resources, Ginger Gregory, reported the acquisition and disposition of common stock related to restricted stock unit vesting and tax withholdings.

Biogen's Chief Accounting Officer, Sean Godbout, reported the vesting of restricted stock units and subsequent sales of common stock for tax purposes.

Biogen's EVP Chief Legal Officer, Susan H. Alexander, acquired common stock through RSU vesting and subsequently sold a portion for tax obligations.

Priya Singhal, Biogen's Head of Development, reported the vesting of restricted stock units and subsequent sale of common stock, including shares withheld for taxes.

Biogen's President and CEO, Christopher Viehbacher, reported the vesting of 7,040 Restricted Stock Units and a subsequent sale of 3,404 shares for tax obligations.

Jane Grogan, Biogen's Head of Research, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

Biogen's Chief Accounting Officer, Sean Godbout, reported the acquisition of common stock through RSU vesting and a subsequent sale for tax withholding purposes.

Biogen's Head of Development, Priya Singhal, exercised restricted stock units and subsequently sold a portion of the resulting common stock.

Biogen's Head of Global Product Strategy, Rachid Izzar, reported the sale of 2,223 shares of common stock for $135 per share, executed under a Rule 10b5-1 trading plan.

Biogen Inc. Director Menelas N. Pangalos was granted 2,370 Restricted Stock Units (RSUs) on June 17, 2025, as reported in a recent SEC Form 4 filing.

Biogen Inc. Director Lloyd Minor reported the acquisition of 2,370 shares of common stock on June 17, 2025, as detailed in a recent SEC Form 4 filing.

Biogen Director Monish Patolawala acquired 2,370 shares of common stock on June 17, 2025, as part of a compensation plan, increasing his total beneficial ownership to 3,710 shares.